GSTP1 and peripheral neuropathy: Molecular mechanism studies demonstrated that FMN had this effect because it could target the activation of the Nrf2 pathway, increase the activity of the phase II metabolizing enzyme glutathione S-transferase pi 1 (GSTP1), and inhibit oxaliplatin-induced peripheral neuropathy by protecting mitochondrial function.